Compare · ARGX vs OTLK
ARGX vs OTLK
Side-by-side comparison of argenx SE (ARGX) and Outlook Therapeutics Inc. (OTLK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and OTLK operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $53.41B, about 274.4x OTLK ($194.7M).
- Over the past year, ARGX is up 52.1% and OTLK is down 32.4% - ARGX leads by 84.5 points.
- OTLK has been more active in the news (3 items in the past 4 weeks vs 1 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 19 for OTLK).
- Company
- argenx SE
- Outlook Therapeutics Inc.
- Price
- $861.30+0.30%
- $1.40-3.79%
- Market cap
- $53.41B
- $194.7M
- 1M return
- -1.91%
- -10.58%
- 1Y return
- +52.05%
- -32.45%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2016
- News (4w)
- 1
- 3
- Recent ratings
- 25
- 19
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Outlook Therapeutics Inc.
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Latest ARGX
- argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
- SEC Form 6-K filed by argenx SE
- argenx to Host Autoimmune Myositis R&D Webinar
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Latest OTLK
- SEC Form S-3 filed by Outlook Therapeutics Inc.
- Outlook Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Outlook Therapeutics Inc.
- SEC Form 8-K filed by Outlook Therapeutics Inc.
- SEC Form 8-K filed by Outlook Therapeutics Inc.
- Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD
- Director Haddadin Yezan Munther bought $24,145 worth of shares (29,000 units at $0.83), increasing direct ownership by 78% to 66,167 units (SEC Form 4)
- Director Sukhtian Ghiath M. bought $5,000,000 worth of shares (8,539,709 units at $0.59) (SEC Form 4)
- SEC Form DEFA14A filed by Outlook Therapeutics Inc.
- SEC Form DEF 14A filed by Outlook Therapeutics Inc.